Tucatinib (Tukysa®). HTA ID: 22058

Assessment Status Awaiting response from Applicant
HTA ID 22058
Drug Tucatinib
Brand Tukysa®
Indication In combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer wo have received at least two prior anti-HER2 treatment regimens.
Rapid review commissioned 23/08/2022
Rapid review completed 20/09/2022
Full pharmacoeconomic assessment commissioned by HSE 28/09/2022
Pre-submission consultation with Applicant 12/12/2023
Full submission received from Applicant 14/03/2024
Assessment process on hold as updated submission required 06/12/2024
Updated submission received 10/03/2025
Preliminary Review sent to Applicant 10/04/2025